Wall Street brokerages forecast that Daré Bioscience, Inc. (NASDAQ:DARE) will announce earnings of ($0.23) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Daré Bioscience’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.15). Daré Bioscience reported earnings per share of ($0.18) in the same quarter last year, which would suggest a negative year over year growth rate of 27.8%. The business is expected to issue its next earnings report on Thursday, May 13th.
On average, analysts expect that Daré Bioscience will report full-year earnings of ($0.79) per share for the current fiscal year, with EPS estimates ranging from ($0.97) to ($0.63). For the next year, analysts expect that the company will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.86) to ($0.62). Zacks’ EPS averages are a mean average based on a survey of analysts that cover Daré Bioscience.
Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings data on Monday, March 29th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.15).
NASDAQ DARE opened at $1.49 on Friday. Daré Bioscience has a 1 year low of $0.91 and a 1 year high of $3.85. The stock has a market capitalization of $70.50 million, a PE ratio of -1.66 and a beta of 2.21. The company’s 50 day simple moving average is $1.68 and its two-hundred day simple moving average is $1.62.
A hedge fund recently raised its stake in Daré Bioscience stock. HighTower Advisors LLC boosted its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 33.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,034 shares of the biotechnology company’s stock after purchasing an additional 8,000 shares during the period. HighTower Advisors LLC owned about 0.08% of Daré Bioscience worth $42,000 as of its most recent SEC filing. 5.33% of the stock is currently owned by hedge funds and other institutional investors.
About Daré Bioscience
DarÃ© Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.
See Also: What is a bull market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.